



Theravance Biopharma, Inc. (NASDAQ: TBPH)

2Q 2018 Financial Results and Business Update
August 1, 2018

Cautionary Statement Regarding Forward-Looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that may cause actual results to differ materially from the forward-looking statements or projections.

Examples of forward-looking statements in this presentation include statements relating to the company's business plans and objectives, including financial and operating results, potential partnering transactions and sales targets, the company's regulatory strategies and timing and results of clinical studies, the potential benefits and mechanisms of action of the company's product and product candidates (including their potential as components of combination therapies).

The company's forward-looking statements are based on the estimates and assumptions of management as of the date of this presentation and are subject to risks and uncertainties that may cause the actual results to be materially different than those projected, such as risks related to delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective (including when our product candidates are studied in combination with other compounds), delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with third parties to discover, develop and commercialize products, risks associated with establishing and maintaining sales, marketing and distribution capabilities.

Other risks affecting the company are described under the heading "Risk Factors" and elsewhere in the company's Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 9, 2018, and other periodic reports filed with the SEC.

Portfolio Advancements in 2018



TD-1473 (JAKi)

Partnership with global leader in Immunology

Global collaboration with Janssen Biotech in inflammatory intestinal disease



TD-9855 (NSRI)

Positive top-line four-week results in nOH

Durable symptom improvements; clinically meaningful benefit in standing SBP



YUPELRI™ (LAMA)

NDA accepted by FDA and under review

Assigned PDUFA date of November 13, 2018




Economic interest in Trelegy serves as an important strategic asset¹

- ✓ Promising initial launch by GSK following approvals in US and EU in late 2017
- ✓ Expanded COPD indication approved by FDA, supported by data from IMPACT study
- ✓ Entitled to upward-tiering royalty of 5.5% - 8.5% of worldwide net sales

TD-9855: Overview of Phase 2 Study in nOH

Study in patients with neurogenic orthostatic hypotension

Three-part design in patients with nOH:



Patients started on Part A, and responders moved to Part B and/or Part C (extension phase)

Purpose: To evaluate the effect of TD-9855 in improving blood pressure and key nOH symptoms

Part C: Responders in Part A eligible for open-label TD-9855 for up to 5 months

- Designed to assess durability of effect
- Primary assessment at four weeks (Day 29)
- Efficacy evaluations: OHSA¹ #1; standing time duration; standing Systolic Blood Pressure (SBP)
- Also assessed safety and PK of TD-9855

TD-9855: Top-line Phase 2 Results in nOH

Parts A and B

A Initial responses observed

Responses reported in majority of patients treated


- 27 of 34 patients enrolled in Part A showed improvements in SBP and/or standing time
- Responses observed above 5 mg

B Confirmation vs. placebo

Statistically significant difference of 30 mm Hg at 4 hours post-dose ($p = 0.011$)

- TD-9855 increased SBP from a low baseline
- SBP dropped on placebo during the day as expected, in response to postural changes and eating
- No evidence of supine hypertension with TD-9855 overnight

Part B Change from Baseline SBP



TD-9855: Top-line Phase 2 Results in nOH

Part C (extension phase)

C

Durability of effect observed in repeat dose extension phase

16 of 21 patients (76%) completed four weeks of treatment

Reductions in symptom severity, with most pronounced benefit in patients with symptomatic nOH¹

- Mean reduction in OSHA #1 = 2.4 at four weeks (n=16)
- 13 completers had OSHA #1 \geq 4 at baseline; **mean reduction in group = 3.8 at four weeks**

Consistent increases in SBP through four weeks

- Clinically meaningful increases in standing SBP (7 mm Hg or greater) after standing for three minutes at all time points on all weekly clinic visits

Generally well tolerated; no serious adverse events assessed as drug-related

Positive results across the three-part study, including durability of effect, provide basis to begin registrational Phase 3 program in nOH in late 2018 or early 2019

TD-1473: Encouraging Findings in Phase 1b Study

4-week treatment in 40 patients with ulcerative colitis


Key Findings

Favorable overall safety and tolerability	No systemic or opportunistic infections (including herpes zoster)
	No evidence of reduce white cell counts
Minimal systemic exposure	Plasma levels of TD-1473 very low
	Consistent in all cohorts to levels observed in healthy volunteers
Biologic activity in GI tract	Rates of clinical response higher for all active doses compared to placebo ¹
	Clinical responses matched by dose-dependent reductions in surrogate biomarkers ²
	Endoscopic improvements and mucosal healing reported in all active arms; none reported in placebo arm
	Rectal bleeding scores improved above placebo at highest two doses
	Dose-related increases in local GI tissue drug concentrations; higher two doses produced mean concentrations above the JAK IC50

Presentation of full results at future medical meeting;
progressing into Phase 2b/3 in UC and Phase 2 in Crohn's disease in 2H 2018

YUPELRI™: PDUFA Date November 13, 2018

Potential as first once-daily nebulized LAMA for COPD



- NDA supported by Phase 3 efficacy and safety studies
- Primary endpoint achieved for both doses in replicate efficacy studies
 - ✓ Robust and sustained improvements in FEV₁
 - ✓ Effective as monotherapy and as add-on to LABA or LABA/ICS
- Generally well tolerated in 12-month safety study

2Q 2018 Financial Highlights

	Three Months Ended, June 30,	
	2018	2017
	(\$, in thousands) Unaudited	
Total Revenue	23,476	3,509
Cost of Goods Sold	(1,448)	1,364
Research and Development ¹	48,621	42,927
Selling, General and Administrative ¹	25,007	24,339
Total Costs and Expenses	72,180	68,630
Operating Loss	(48,704)	(65,121)
<i>¹Amounts include share-based compensation expense below</i>		
Research and Development	6,904	4,917
Selling, General and Administrative	6,951	5,481
Total Share-based Compensation Expense	13,855	10,398
Operating Loss excluding Share-based Compensation	(34,849)	(54,723)
Cash, Cash Equivalents and Marketable Securities as of June 30, 2018	371,155	

GSK's Trelegy Ellipta Offers Significant Potential

First and only once-daily single inhaler triple therapy


Economic interest in Trelegy Ellipta serves as an important strategic asset

- Upward-tiering royalty 5.5% - 8.5% of worldwide net sales¹
- Passive economic interest; no product cost obligations

Program Summary

- Approved for COPD in US and EU²
- FF/UMEC/VI: Comprise of ICS, LAMA, and LABA, active components of Breo[®] (FF/VI) and Anoro[®] (UMEC/VI)
- Phase 3 CAPTAIN asthma study in progress

Strongest US Ellipta launch to date



Launched in US in November 2017

Source: GSK; IQVIA NPA weekly TRx data



Economic interest in Trelegy serves as an important strategic asset¹

- ✓ Promising initial launch by GSK following approvals in US and EU in late 2017
- ✓ Expanded COPD indication approved by FDA, supported by data from IMPACT study
- ✓ Entitled to upward-tiering royalty of 5.5% - 8.5% of worldwide net sales

Focus on Strategic Priorities

Commitment to developing transformational medicines

Opportunities to Create Transformational Medicines	YUPELRI™ (revefenacin)	Nebulized LAMA in COPD (PDUFA date November 13, 2018)
	TD-1473	Intestinally-restricted JAK inhibitor for inflammatory intestinal diseases
	TD-9855	NSRI in symptomatic neurogenic orthostatic hypotension
	TD-8236	Inhaled JAK inhibitor for serious respiratory diseases
	Research	R&D Day to highlight new programs advancing towards clinic

Strategic Asset	Trelegy Ellipta	(FF/UMEC/VI) Single inhaler triple therapy in COPD
-----------------	-----------------	--

Managed by GSK and Innoviva¹



Q&A

Thank you